文献速递静脉血栓栓塞

经验性全身抗凝与重症甲型H1N1 ARDS患者静脉血栓栓塞减少相关

Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2018-11-23

本研究在单中心990张床位的学术三级医院外科重症监护病房开展观察性队列研究,纳入可能为H1N1病毒性肺炎的重症ARDS危重患者,对全部患者早期启动经验性全身肝素静脉输注作为VTE预防策略。结果显示H1N1是VTE和肺栓塞的独立危险因素,经验性全身抗凝显著减少H1N1阳性患者血栓事件,且未增加出血并发症。

要点

  • H1N1重症ARDS患者肺栓塞风险升高23.3倍、VTE风险升高17.9倍。
  • 经验性全身肝素抗凝显著降低H1N1阳性患者血栓事件,未增加出血并发症。
  • 校正H1N1状态后,未接受经验性抗凝者发生VTE的可能性为接受者的33倍(P = .01)。

核心结论

  • 重症H1N1 ARDS患者静脉血栓并发症风险增加,尤其是肺血栓栓塞。
  • 在该队列中经验性全身肝素抗凝显著降低VTE发生率,且未增加出血并发症。

研究设计与样本

  • 单中心990张床位学术三级医院外科重症监护病房的观察性队列研究。
  • 研究对象为可能为H1N1病毒性肺炎的危重重症ARDS患者。
  • 对全部可能为H1N1病毒性肺炎的重症ARDS患者早期启动经验性全身肝素静脉输注作为VTE预防策略。

主要发现

  • VTE的独立危险因素包括H1N1、培养阳性细菌性肺炎和需要血管升压药。
  • 肺栓塞的独立危险因素包括H1N1、培养阳性细菌性肺炎和男性。
  • H1N1 ARDS患者肺栓塞风险升高23.3倍,VTE风险升高17.9倍。
  • Kaplan-Meier分析和log-rank检验证实经验性全身肝素抗凝对H1N1阳性患者血栓事件有显著保护作用,对H1N1阴性患者无此保护作用。
  • 校正H1N1状态后,未接受经验性全身抗凝者发生任何VTE的可能性为接受经验性全身肝素抗凝者的33倍(P = .01)。

关键数值与推荐

  • 未接受经验性全身抗凝者任何VTE风险为接受者的33倍(P = .01)。

临床怎么用

  • 对重症H1N1 ARDS患者应高度警惕静脉血栓栓塞,尤其是肺血栓栓塞。
  • 可考虑对重症H1N1 ARDS患者早期经验性全身肝素抗凝以预防VTE。
  • 该策略在本队列中未增加出血并发症,但需结合患者个体出血风险评估。

局限性

  • 为单中心观察性队列研究,非随机对照设计。
  • 研究对象为可能H1N1病毒性肺炎的重症ARDS患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An association between increased venous thromboembolism (VTE) events and influenza A H1N1 (H1N1) was noted in the first 10 patients with severe acute respiratory distress syndrome (ARDS). An empirical systemic anticoagulation protocol (heparin intravenous infusion) was initiated when autopsy of patients with severe hypoxemia confirmed multiple primary pulmonary thrombi and emboli. The purpose of this study was to examine the relationship between H1N1 and VTE events and to assess the efficacy of empirical systemic heparin anticoagulation in preventing VTE and death in H1N1 severe ARDS patients. METHODS: An observational cohort study of critically ill severe ARDS patients with possible H1N1 viral pneumonia was performed in a surgical intensive care unit in a single 990-bed academic tertiary care center. Early empirical systemic heparin anticoagulation for all severe ARDS patients with possible H1N1 viral pneumonia was initiated as a VTE preventive strategy. RESULTS: Univariate comparisons and multivariate logistic regression were used to identify risk factors for VTE. Independent risk factors for VTE included H1N1, culture-positive bacterial pneumonia, and vasopressor requirement. Independent risk factors for pulmonary embolism included H1N1, culture-positive bacterial pneumonia, and male sex. H1N1 ARDS patients had 23.3-fold higher risk for pulmonary embolism and 17.9-fold increased risk for VTE. Kaplan-Meier analysis and log-rank test confirmed that empirical systemic heparin anticoagulation provided significant protection from thrombotic events in the H1N1-positive but not in the H1N1-negative critically ill ARDs patients. In multivariate analysis, adjusting for H1N1 status, patients without empirical systemic anticoagulation were 33 times more likely to have any VTE compared with those treated with empirical systemic heparin anticoagulation (P = .01). CONCLUSIONS: Critically ill patients with H1N1 ARDS have increased risk of venous thrombotic complications, particularly pulmonary thromboembolism. Empirical systemic heparin anticoagulation in this cohort of patients significantly reduced VTE incidence without increased hemorrhagic complications.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 30477976. doi:10.1016/j.jvsv.2018.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。